Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 18:00 ET | Source: Teva Pharmaceutical Industries Ltd

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO...
November 03, 2025 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain...
September 20, 2025 22:16 ET | Source: Teva Pharmaceutical Industries Ltd

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported...
September 20, 2025 22:15 ET | Source: Teva Pharmaceutical Industries Ltd

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic...
March 31, 2025 13:00 ET | Source: Teva Pharmaceutical Industries Ltd

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1New data from UZEDY®...
January 27, 2025 06:00 ET | Source: Teva Pharmaceutical Industries Ltd; Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
October 22, 2024 07:00 ET | Source: Teva Pharmaceutical Industries Ltd

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
October 03, 2024 08:30 ET | Source: Teva Pharmaceutical Industries Ltd; mAbxience

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and adds...
May 17, 2024 16:04 ET | Source: NurExone Biologic Inc

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations
April 13, 2020 09:30 ET | Source: Connectyx Technologies Holdings Group, Inc

Connectyx Technologies Holdings Group Returns to OTC Current Status

More than $350,000 of Convertible Debt Eliminated BOCA RATON, FL, April 13, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group (OTC PINK: CTYX) has filed all required annual reports...